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Abstract
Background: Elevated mean platelet volume (MPV) has been recently discussed as a predic-
tor of death in patients with acute coronary syndrome (ACS), but the cut-off point of MPV in 
relation to poor prognosis has not been estimated so far. The aim of this study was to evaluate 
MPV and its prognostic value in ACS complicated by cardiogenic shock (CS). Such an analy-
sis in patients with the most serious and fatal complication of ACS has not been performed in 
previously published research.
Methods: Fifty three patients with ACS complicated by CS (age 68.9 ± 11.4, 49% women, 
92% STEMI, 55% fatal CS) and 53 age- and gender-matched patients with uncomplicated 
ACS as a control group (age 69.1 ± 10.6, 49% women, 92% STEMI, 0% fatal) were included 
in our prospective study from 2010 to 2012. All the patients underwent successful primary 
percutaneous coronary intervention. MPV was determined on admission (MPV1) and in conse-
cutive two days of hospitalization (MPV2, MPV3). The blood sample was analyzed immediately 
after collection in EDTA tubes using an automatic blood counter.
Results: MPV1 was similar in both groups (8.91 ± 1.11 fl vs. 8.57 ± 0.74 fl, NS). Further-
more, there were no statistically significant differences in MPV value in fatal and nonfatal CS 
(8.90 ± 1.18 fl vs. 8.93 ± 1.05 fl, NS).
Conclusions: The above results suggest that MPV cannot be considered a predictor of poor 
in-hospital outcome in patients with ACS complicated by cardiogenic shock. (Cardiol J 2013; 
20, 3: 254–260)
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Introduction
Despite great progress in the treatment of 
acute coronary syndromes (ACS), patients with 
cardiogenic shock (CS) still remain a group at the 
greatest risk of death. Simple, easily measurable 
prognostic factors are sought to distinguish those 
patients who are at risk of death despite successful 
recanalization of infarct related artery in CS group.
Platelets are non-nucleated blood cells which 
play a crucial role in the process of coagulation. 
Their function is strongly associated with atheroge-
nesis and atherothrombosis — processes important 
in pathogenesis of cardiovascular diseases [1]. 
Mean platelet volume (MPV) is a widely available 
parameter of platelet size and function — it is 
simply measured in most of commonly used blood 
analyzers, but not yet used in clinical practice.
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MPV is a parameter which states platelet size 
and indirectly proves its activity. It is known that 
larger platelets are more reactive due to higher 
concentration of active substances in microgranu-
les (e.g. thromboxane A2 and B2, platelet factor 4, 
P-selectin, platelet-derived growth factor) and 
expression of adhesive receptors (glycoprotein 
IIb/IIIa) [2]. Furthermore, increased MPV values 
are associated with shortened bleeding time [3]. 
MPV is considered a useful prognostic mar-
ker of cardiovascular risk [2, 4, 5]. In general 
population, higher MPV value is associated with 
increased occurrence of myocardial infarction (MI) 
[2]. Klovaite et al. [6] found that in general Danish 
population the risk of MI has increased by 38% in 
individuals with MPV ³ 7.4 vs. < 7.4 fl indepen-
dently of known cardiovascular risk factors. Increa-
sed MPV value was observed also in patients with 
hypertension, impaired fasting glucose, diabetes 
mellitus, hypercholesterolemia and obesity [4, 7].
Increased MPV has been discussed recently as 
a predictor of death in patients with ACS, but the 
cut-off point of MPV in relation to poor prognosis 
has not been estimated so far [2, 4]. MPV value 
and its clinical significance has not been analyzed 
in patients with ACS complicated by CS yet. There-
fore, we focused on this issue in the present study.
Methods
Study population
All consecutive patients with ACS complicated 
by cardiogenic shock (CS [+] group), admitted to 
the Intensive Cardiac Therapy Clinic during the 
period from January 2010 to April 2012 and treated 
with successful primary percutaneous coronary 
intervention (PCI) were included in our prospec-
tive study. Age- and gender-matched patients with 
uncomplicated ACS were selected as a  control 
group (CS [–] group) (Table 1).
Study protocol
The diagnosis of ST elevation myocardial 
infarction (STEMI) was confirmed using the con-
temporary definition of acute MI including typical 
clinical symptoms, persistent ST segment eleva-
tion ³ 0.2 mV in two of V2–V3 leads or ³ 0.1 mV 
in two of other contiguous leads or new left bundle 
branch block in ECG and elevation of myocardial 
necrosis markers (troponin T, creatinine kinase-
-MB fraction) [8]. The diagnosis of non STEMI 
(NSTEMI) was made on the basis of typical chest 
pain and elevated cardiac biomarkers after exclu-
sion of elevation of ST-segment in electrocardio-
graphy [9]. CS was defined as a clinical state of 
Table 1. Baseline characteristic of patients with and without cardiogenic shock.
CS (+), n = 53 CS (–), n = 53 P
Female 26 (49%) 26 (49%) 1.00
Male 27 (51%) 28 (51%) 0.85
Age [years] 68.9 ± 11.4 69.1 ± 10.6 0.65
STEMI 49 (92%) 49 (92%) 1.00
NSTEMI 4 (8%) 4 (8%) 1.00
Prior MI 12 (23%) 9 (17%) 0.46
Smokers 28 (53%) 29 (55%) 0.84
Multivessel disease 26 (57%) 24 (45%) 0.69
Diabetes 12 (23%) 14 (26%) 0.65
Hypertension 29 (55%) 36 (68%) 0.16
Fatal outcome 29 (55%) 0 (0%) < 0.001
Laboratory results:
Blood glucose level [mmol/L] 14.76 ± 6.68 8.8 ± 2.85 < 0.001
Red blood cells [106/mm3] 4.49 ± 0.57 4.51 ± 0.58 0.97
White blood cells [103/mm3] 11.16 ± 3.09 11.27 ± 3.33 0.86
Platelets [103/mm3] 241.25 ± 68.47 248.74 ± 68.08 0.58
MPV1 [fl] 8.78 ± 0.89 8.57 ± 0.74 0.25
CS (+) — patients with cardiogenic shock, study group; CS (–) — patients without cardiogenic shock, control group; STEMI — ST-seg-
ment elevation myocardial infarction; NSTEMI — non-ST-segment elevation myocardial infarction; MI — myocardial infarction;  
MPV1 — mean platelet volume on admission; fl — femtoliter
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hypoperfusion characterized by a systolic pres-
sure < 90 mm Hg (or administration of inotropes 
and/or intra-aortic balloon pump to maintain sy-
stolic blood pressure > 90 mm Hg), oliguria and 
altered mental status. Other causes of hypotension 
such as hypovolemia, vasovagal reactions, elec-
trolyte disturbances, pharmacological side-effects, 
tamponade or arrhythmias were excluded [8]. Pa-
tients with CS as a result of mechanical complica-
tions of MI (ventricular septal rupture, acute mitral 
valve regurgitation) were not included in the study.
Baseline characteristics were obtained for all 
patients. Demographic data, cardiovascular history, 
risk factors (hypercholesterolemia, smoking status, 
hypertension, and diabetes mellitus), and prior 
embolic events were recorded. We also analyzed 
the clinical course of hospitalization. Left ventri-
cular function was assessed by echocardiographic 
examination. Left ventricular end-diastolic and 
end-systolic volumes and ejection fraction were 
determined from apical 2- and 4-chamber views 
using Simpson’s biplane formula.
The angiographic severity of coronary artery 
disease (CAD) was assessed visually using 2 ortho-
gonal views by 2 observers blind to the clinical and 
echocardiographic details. Single-vessel CAD was 
defined as at least 70% stenosis of only one major 
epicardial artery. Multi-vessel disease was defined 
as the occurrence of more than one critical stenosis 
of at least 70% in a major coronary artery and/or of 
at least 50% in the left main coronary artery. The 
infarct-related artery was identified on the basis of 
electrocardiography and coronary angiography fin-
dings. In general, only the infarct-related artery was 
treated during emergency catheterization. PCI was 
performed using standard equipment and techniqu-
es including stent implantation. The angiographic 
success of revascularization was defined as the 
Thrombolysis In Myocardial Infarction (TIMI) 3 flow.
All patients underwent basic laboratory tests 
including blood count, electrolytes, coagulation, 
renal and hepatic parameters, markers of myocar-
dial necrosis and blood glucose levels. MPV was 
determined on admission and in consecutive 2 days 
of hospitalization. The blood sample was analyzed 
immediately after collection in EDTA tubes using 
an automatic blood counter ABX Pentra XL 80.
The study was approved by the local research 
ethic committee and all patients were asked for 
written informed consent.
Statistical analysis
Statistical analysis of the data was carried out 
using Statistica 7.0 set. Continuous variables were 
presented as means ± SD. Comparisons between 
groups were performed using the c2 test, non-
-parametric Mann-Whitney test, Friedman test and 
Wilcoxon test for pairs (post-hoc analysis). Statisti-
cal significance was assumed at a p value of < 0.05.
Results
Fifty three patients were included in our study; 
53 age- and gender-matched consecutive patients 
with uncomplicated ACS were selected as a control 
group. The mean age of patients was 68.9 ± 11.4 
vs. 69.1 ± 10.6 years respectively with 26 (49%) 
women and 27 (51%) men in both groups. There 
were 92% STEMIs and 8% NSTEMIs both in study 
and control group. A mortality rate in patients with 
cardiogenic shock was 29 (55%) patients which is 
consistent with previous studies. The majority of 
deaths (16 patients) occurred on the first day of 
hospitalization. All patients from the control group 
survived. Risk factors were evenly distributed in 
both groups.
MPV1 was similar in both groups (8.91 ± 1.11 fl  
vs. 8.57 ± 0.74 fl, NS) (Fig. 1). In subsequent 
days of hospitalization mean MPV was increasing 
in patients with and without CS, but more in the 
latter. In study group, the increase in MPV value 
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Figure 1. Mean platelet volume on admission in study 
population; MPV1 — mean platelet volume on admis-
sion; CS (+) group — patients with cardiogenic shock, 
study group; CS (–) group — patients without cardioge-
nic shock, control group; fl — femtoliter.
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was significant when comparing MPV value on 
admission and on the third day (8.91 ± 1.11 fl vs. 
9.39 ± 0.95 fl, MPV1 vs. MPV3 z = 2.848, p < 0.01). 
In contrast, in control group MPV was significantly 
increasing in consecutive days (MPV1: 8.57 ± 0.74 fl, 
MPV1 vs. MPV2 z = 4.178, p <0.001; MPV2: 8.84 ± 
± 0.86 fl, MPV1 vs. MPV3 z = 4.678, p < 0.001; 
MPV3: 9.11 ± 0.89 fl, MPV2 vs. MPV3 z = 2.818; 
p < 0.01). Mean MPV was significantly higher in 
patients with CS in comparison to control group only 
on the second day after onset of symptoms (MPV2: 
9.19 ± 0.8 fl vs. 8.84 ± 0.86, p < 0.05) (Table 2). 
Furthermore, there were no statistically significant 
differences in MPV1 value in fatal and nonfatal CS 
(8.90 ± 1.18 fl vs. 8.93 ± 1.05 fl, NS) (Table 3). In 
the multiple stepwise logistic regression analysis 
of biochemical (MPV1, blood glucose and creatinine 
level) and clinical factors (age, sex, history of diabe-
tes) none of the factors was found to be a predictor 
of death in CS (+) group. In addition, no correlation 
was found between MPV1 and blood glucose level on 
admission in CS (+) (r = –0.1702, p = 0.22) and in 
CS (–) group (r = 0.1207, p = 0.4) likewise (Fig. 2).
Discussion
Platelets are formed in the bone marrow from 
the polyploid megakaryocytes. Their volume is 
regulated by molecular mechanisms and growth 
factors and doesn’t correlate with the age of plate-
lets [2]. It is influenced by thrombopoietin (TPO), 
interleukin-6 and -3 [2]. TPO is a main regulator 
of megakaryocytopoiesis. It also stimulates alpha 
granule secretion from platelets and enhances 
their ability to aggregate [10]. TPO was positively 
correlated with MPV in ACS patients in the report 
of Senaran et al. [11]. 
It is known that, among other blood para-
meters, platelets count and mean platelet volu-
me are mostly inheritable. Meisinger et al. [12] 
identified three loci and three common single-
-nucleotide polimorphisms associated with MPV, 
which stand for about 5% of MPV value varian-
ces in population. In Soranzo et al. [13] genome 
wide association study one quantitative trait loci 
associated with MPV, located at 12q24, was also 
a risk locus for CAD. It requires further studies and 
their results may contribute to the understanding 
of the relationship between MPV, platelets function 
and cardiovascular risk [12, 14].
There is no relevant difference between MI 
and unstable angina group in contrast with stable 
angina, in which mean MPV is on a similar level 
as in healthy controls [2, 15]. Likewise, MPV 
is higher in MI with normal coronary arteries 
compared to control subjects [16]. The important 
clinical implication of MPV is its predictive value 
of coronary angioplasty effectiveness. The Chu 
Table 3. Comparison of mean platelet volume in patients with fatal and non-fatal cardiogenic shock in 
consecutive days.
Fatal CS Non-fatal CS z value p value
x SD x SD
MPV1 [fl] 8.90 1.18 8.93 1.05 0.232 > 0.05
MPV2 [fl] 9.25 0.80 9.16 0.81 0.382 > 0.05
MPV3 [fl] 9.35 0.83 9.40 1.00 0.135 > 0.05
CS — patients with cardiogenic shock, study group; MPV1 — mean platelet volume on admission; MPV2 — mean platelet volume in the 
second day; MPV3 — mean platelet volume in the third day; SD — standard deviation; fl — femtoliter
Table 2. Comparison of mean platelet volume in patients with and without cardiogenic shock in conse-
cutive days.
CS (+) CS (–) z value p value
x SD x SD
MPV1 [fl] 8.91 1.11 8.57 0.74 1.365 > 0.05
MPV2 [fl] 9.19 0.80 8.84 0.86 1.989 < 0.05
MPV3 [fl] 9.39 0.95 9.11 0.89 1.132 > 0.05
CS (+) — patients with cardiogenic shock, study group; CS (–) — patients without cardiogenic shock, control group; MPV1 — mean plate-
let volume on admission; MPV2  — mean platelet volume on the second day; MPV3 — mean platelet volume on the third day; SD —  stan-
dard deviation; fl — femtoliter
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et al. [2] study has shown significantly higher 
baseline mean MPV in patients who developed 
restenosis than in those who did not develop such 
a complication. A similar correlation was found by 
Huczek et al. [17]. Also the study by Taglieri et 
al. [7] revealed a  trend toward higher incidence 
of stent thrombosis. Duygu et al. [18] considered 
MPV a useful hematological marker allowing iden-
tification of patients with stable CAD who are at 
higher risk of post-PCI low-reflow.
Elevated MPV has been discussed recently as 
a predictor of death in patients with ACS, but the 
cut-off point of MPV in relation to poor prognosis 
has not been estimated so far.
In some studies conducted in AMI, elevated 
MPV was associated with higher risk of death 
and recurrent infarction not only in hospital but 
also during the 2 years observation after ACS [2, 
19–22]. Taglieri et al. [7] investigated higher risk 
of primary end-point, composed of cardiovascular 
death and re-MI at 1 year after ACS in patients 
with NSTEMI with MPV ³ 8.9 fl. Chu et al. [2] re-
ported the 2-fold increase in mortality among acute 
MI patients with MPV cut off point of ³ 10.3 fl in 
comparison to a group with the cut-off point of 9 fl 
[2]. In the study by Dogan et al. [23] major cardiac 
outcome (consisting of the composite end-point 
of cardiac death, MI, recurrent angina and hospi-
talization) in NSTEMI patients at 12 months was 
significantly higher in group with MPV > 9.9 fl 
(39% vs. 26%, p = 0.016). Some values of higher 
risk are postulated in research, but the increase of 
cardiovascular risk may remain in linear relation-
ship with increasing MPV.
On the contrary, Lopez-Cuenca et al. [24] re-
vealed that MPV did not show an independent pro-
gnostic significance at 6-month follow-up in their 
NSTEMI group. Azab et al. [25] found that MPV/ 
/platelet count ratio is superior to the MPV alone 
in predicting long-term mortality after NSTEMI. 
They suggested that usage of this ratio would 
magnify the relationship between platelet indices 
and mortality after NSTEMI.
In our study we evaluated the prognostic 
value of MPV in ACS complicated by cardio-
genic shock. Such an analysis in patients with 
the most serious and fatal complication of ACS 
has not been performed so far. Mean MPV was 
significantly higher in patients with CS in com-
parison to the control group only in the second 
day after onset of symptoms (MPV2). There were 
no statistically significant differences in MPV 
value in fatal and nonfatal CS. We proved that 
MPV could not be considered as a predictor of 
Figure 2. Correlation between mean platelet volume and blood glucose level on admission in patients with and with-
out cardiogenic shock, respectively; MPV1 — mean platelet volume on admission; CS (+) — patients with cardiogenic 
shock, study group; CS (–) — patients without cardiogenic shock, control group; fl — femtoliter.
CS (+): r = –0.1702; p = 0.2230 CS (–): r = –0.1207; p = 0.3989
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poor in-hospital outcome in patients with ACS 
complicated by cardiogenic shock.
Diabetic patients are in danger of micro- and 
macrovascular complications. Hyperglycemia le-
ads to endothelial damage through oxidative and 
osmotic stress, advanced glycation end products, 
decreased nitrogen monoxide production and epi-
genetic changes in gene promoters resulting in 
persistent inflammation [26]. Platelet dysfunction 
and increased thromboxane A2 synthesis lead to 
prothrombotic state in diabetes mellitus [27]. Zube-
ri et al. [28] have reported that MPV is increased in 
hyperglycemia states — its value rises significantly 
from non-diabetic patients through impaired fast-
ing glucose patients to diabetic population group 
(mean MPV 8.63 fl, 8.98 fl, 9.34 fl, respectively). It 
means that changes in megacaryocyte — platelet 
axis which occur before ACS may be similar to 
those present in pre-diabetic conditions. Klodiatte 
et al. [29] suggested that MPV would be a useful 
prognostic marker of cardiovascular complications 
in diabetes. They found that increase in HbA1c 
concentration was directly proportional to increa-
sed MPV in their diabetic group composed of 255 
individuals. The mean MPV in the subgroup with 
HbA1c < 6.5% was significantly lower in compa-
rison to the subgroup with HbA1c > 6.5% (7.95 ± 
± 0.72 fl vs. 8.35 ± 0.72 fl). However, in our study, 
we found no correlation between MPV1 and blood 
glucose level on admission neither in patients with 
cardiogenic shock nor in the control group. There is 
no evidence that osmotic stress can cause platelets 
enlargement through higher permeability of the 
cellular membrane.
Limitations of the study
The small group of patients is the most im-
portant limitation of this study. Cardiogenic shock 
develops in 6–9% of patients with ACS. The high 
mortality rate in CS results in loss of data for ana-
lysis in consecutive days. There were no studies 
devoted to assessment of the predictive value of 
MPV in patients with cardiogenic shock, therefore 
further studies on this topic are required to confirm 
our results.
Conclusions
The above results from our relatively small 
group suggest that MPV could not be considered 
a predictor of poor in-hospital outcome in patients 
with ACS complicated by cardiogenic shock.
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